Current practice and surgical outcomes of neoadjuvant chemotherapy for early breast cancer: UK NeST study
- PMID: 35543289
- PMCID: PMC10364769
- DOI: 10.1093/bjs/znac131
Current practice and surgical outcomes of neoadjuvant chemotherapy for early breast cancer: UK NeST study
Erratum in
-
Corrigendum to: Current practice and surgical outcomes of neoadjuvant chemotherapy for early breast cancer: UK NeST study.Br J Surg. 2022 Dec 13;110(1):124. doi: 10.1093/bjs/znac282. Br J Surg. 2022. PMID: 36075875 Free PMC article. No abstract available.
Figures
References
-
- Makris A, Powles T, Ashley S, Chang J, Hickish T, Tidy V et al. A reduction in the requirements for mastectomy in a randomized trial of neoadjuvant chemoendocrine therapy in primary breast cancer. Ann Oncol 1998;9:1179. - PubMed
-
- Kuerer HM, Hunt KK, Newman LA, Ross MI, Ames FC, Singletary SE. Neoadjuvant chemotherapy in women with invasive breast carcinoma: conceptual basis and fundamental surgical issues. J Am Coll Surg 2000;190:350–363 - PubMed
-
- Loibl S, O’Shaughnessy J, Untch M, Sikov WM, Rugo HS, McKee MD et al. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial. Lancet Oncol 2018;19:497–509 - PubMed
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
